N-(1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide | 677304-98-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: N-(1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide
• 英文别名: N-{1-azabicyclo[2.2.2]octan-3-yl}-2H-indazole-3-carboxamide；N-(1-azabicyclo[2.2.2]octan-3-yl)-1H-indazole-3-carboxamide
• CAS: 677304-98-2
• 化学式: C₁₅H₁₈N₄O
• 分子量: 270.334
• InChiKey: TXCYUSKWBHUVEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  61
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-aminoquinuclidine dihydrochloride 、 吲唑-3-羧酸 在 4-二甲氨基吡啶 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 2.0h， 以50%的产率得到N-(1-azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide
  参考文献：
  名称：

  [EN] INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF
  [FR] INDAZOLES, BENZOTHIAZOLES ET BENZOISOTHIAZOLES, LEUR PREPARATION ET LEURS UTILISATIONS

  摘要：

  本发明涉及一般与尼古丁乙酰胆碱受体（nAChR）的配体、nAChR的激活以及与缺陷或功能失常的尼古丁乙酰胆碱受体相关的疾病病况的领域。此外，该发明涉及新颖化合物（吲唑和苯并噻唑），它们作为α7 nAChR亚型的配体，制备这类化合物的方法，含有这类化合物的组合物，以及使用这些方法。

  公开号：

  WO2004029050A1

文献信息

• METHODS FOR THE PREPARATION OF INDAZOLE-3-CARBOXYLIC ACID AND N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT
  申请人：Kuang Shan-Ming

  公开号：US20110172428A1

  公开（公告）日：2011-07-14

  The present invention provides novel methods for preparing indazole-3-carboxylic acid 2, a key starting material for the manufacture of agonists or partial agonists of the nicotinic α-7 receptor, such as N—(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide HCl salt 13. Nicotinic α-7 receptor agonists and partial agonists are being useful in the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain, such as for the treatment of Alzheimer's disease and schizophrenia, as well as other psychiatric and neurological disorders. The present methods are useful for preparing indazole-3-carboxylic acid on scaled-up levels.

  本发明提供了制备吲唑-3-羧酸2的新方法，该物质是制造尼古丁α-7受体激动剂或部分激动剂的关键起始物质，例如N—(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide HCl盐13。尼古丁α-7受体激动剂和部分激动剂在治疗与缺陷或功能失常的尼古丁乙酰胆碱受体相关的疾病状况中很有用，尤其是大脑相关的疾病，如治疗阿尔茨海默病和精神分裂症，以及其他精神疾病和神经系统疾病。目前的方法适用于大规模制备吲唑-3-羧酸。
• Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
  申请人：——

  公开号：US20040132790A1

  公开（公告）日：2004-07-08

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the &agr;7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明通常涉及乙酰胆碱受体配体（nAChR）、nAChR激活以及与缺陷或功能障碍的乙酰胆碱受体相关的疾病状态的治疗领域，特别是大脑。此外，本发明涉及新型化合物（吲唑和苯并噻唑），其作为α7 nAChR亚型的配体，制备此类化合物的方法，含有此类化合物的组合物，以及使用此类化合物的方法。
• INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF
  申请人：Xie Wenge

  公开号：US20080154037A1

  公开（公告）日：2008-06-26

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明涉及尼古丁乙酰胆碱受体(nAChR)的配体、nAChR的激活以及与缺陷或功能失常的尼古丁乙酰胆碱受体相关的疾病状态的治疗，特别是大脑的治疗。此外，本发明涉及新型化合物(吲唑和苯并噻唑)，其作为α7 nAChR亚型的配体，制备此类化合物的方法，包含此类化合物的组合物以及使用此类化合物的方法。
• Indazoles, Benzothiazoles, and Benzoisothiazoles, and preparation and uses thereof
  申请人：Memory Pharmaceuticals Corporation

  公开号：EP2305675A1

  公开（公告）日：2011-04-06

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the alpha7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

  本发明一般涉及烟碱乙酰胆碱受体（nAChR）的配体、nAChR 的活化以及与烟碱乙酰胆碱受体缺陷或功能失调相关的疾病（尤其是脑部疾病）的治疗领域。此外，本发明还涉及作为α7 nAChR亚型配体的新型化合物（吲唑类和苯并噻唑类）、制备此类化合物的方法、含有此类化合物的组合物及其使用方法。
• Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
  申请人：Novartis AG

  公开号：US11359241B2

  公开（公告）日：2022-06-14

  The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.

  本发明提供了预测患有认知障碍或功能障碍、精神病和/或神经退行性疾病的受试者对α7烟碱乙酰胆碱受体激活剂治疗反应性的方法。